Study advancing the use of 19F tracer agent in clinical immuno-oncology applications is published in Contrast Media & Molecular Imaging
September 19, 2014 – Pittsburgh, Pennsylvania
Celsense, Inc., announced today that the first clinical results using the Cell Sense tracer agent have been published in the peer-reviewed scientific journal Magnetic Resonance in Medicine. This article describes magnetic resonance imaging (MRI) results from a clinical study evaluating the ability to detect a dendritic cell vaccine, labeled with Cell Sense, which was administered to patients with colorectal cancer. The study demonstrates that the Cell Sense technology is effective at imaging and quantifying the administered dendritic cells in a clinical setting. The study was conducted at the University of Pittsburgh Cancer Institute under an Investigational New Drug application authorized by the US Food and Drug Administration. It was funded by a multi-year grant from the National Cancer Institute at the National Institutes of Health.
“We are delighted to report the results of this initial clinical study. The Cell Sense platform can provide valuable feedback to the investigators on the initial delivery and behavior of the therapeutic cells. I expect future studies will incrementally build on this early work, and that MRI cell tracking data will lead to a paradigm shift in how cell therapies are developed,” said Charlie O’Hanlon, the President and CEO of Celsense, Inc. and a co-author of the article.
A link to the full, open-access manuscript is available at:
Related University of California press release:
About Cell Sense
Cell Sense is a patented perfluorocarbon tracer agent used to non-invasively image the administration, migration, and persistence of cells transplanted for therapeutic or diagnostic purposes using MRI. Cell Sense is the subject of Drug Master Files at the US Food and Drug Administration and Health Canada, and is available for use in preclinical and clinical studies. Applications include tracking cells in immunotherapy and regenerative medicine, as well as diagnosis of inflammatory sites by tracking selected populations of immune cells. Using Voxel Tracker, a software suite developed by Celsense, investigators can quantify the number of labeled cells in a user-specified region of interest.
About Celsense, Inc.
Celsense, Inc. develops and markets novel products that enable the non-invasive imaging of populations of cells in vivo using MRI. Customers include leading pharmaceutical and biotechnology companies, as well as medical research centers worldwide. Celsense’s mission is to be the standard for cellular imaging in human health.
Charlie O’Hanlon, President and CEO
Real-Time Results,<br />Faster and More Accurate
Celsense offers products that enable real-time MRI detection of inflammation and cellular therapeutics. The mission of the company is to be the standard for cellular imaging in human health.
GET IN TOUCH
Send Us A Message
© 2018 Celsense, Inc. All rights reserved.